Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H12N2O5 |
| Molecular Weight | 300.2662 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC=C(C=C1)\N=N\C2=CC(C(O)=O)=C(O)C=C2
InChI
InChIKey=FNRNBCNUWGWVFO-WUKNDPDISA-N
InChI=1S/C15H12N2O5/c18-13-6-5-11(8-12(13)15(21)22)17-16-10-3-1-9(2-4-10)7-14(19)20/h1-6,8,18H,7H2,(H,19,20)(H,21,22)/b17-16+
| Molecular Formula | C15H12N2O5 |
| Molecular Weight | 300.2662 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:12:51 GMT 2023
by
admin
on
Sat Dec 16 12:12:51 GMT 2023
|
| Record UNII |
QIU74LKJ78
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
402934-69-4
Created by
admin on Sat Dec 16 12:12:52 GMT 2023 , Edited by admin on Sat Dec 16 12:12:52 GMT 2023
|
PRIMARY | |||
|
QIU74LKJ78
Created by
admin on Sat Dec 16 12:12:52 GMT 2023 , Edited by admin on Sat Dec 16 12:12:52 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Chemical synthesis of NOBEX-AA-004; In preliminary experiments, NOBEX-AA-004 (50 and 100 mg/kg b.i.d. orally for 10 days) exhibited antiinflammatory effects. lass: Anti-inflammatory, Small molecule; Mechanism of Action: Immunomodulator; Highest Development Phase: Discontinued for Inflammatory bowel diseases; Most Recent Events: 30 Jun 2004 Nobex has completed a phase I/II trial in Inflammatory bowel disease in USA, 09 Jun 2004 Phase-I/II clinical trials in Inflammatory bowel disease in USA (PO)
|
